The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction - Wikidata - wikimedia - TriplyDB

The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction

The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction

http://www.wikidata.org/entity/Q27024279

about

Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease The role of titin and extracellular matrix remodelling in heart failure with preserved ejection fraction Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study Pathophysiology and the cardiorenal connection in heart failure. Circulating hormones: biomarkers or mediators.Prevention of PKG1α oxidation augments cardioprotection in the stressed heart.Pro-Atrial Natriuretic Peptide: A Novel Guanylyl Cyclase-A Receptor Activator That Goes Beyond Atrial and B-Type Natriuretic Peptides.Unbalanced Oxidant-Antioxidant Status: A Potential Therapeutic Target for Coronary Chronic Total Occlusion in Very Old Patients.INDIE-HFpEF (Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure With Preserved Ejection Fraction): Rationale and Design.G protein-coupled receptor 35: an emerging target in inflammatory and cardiovascular disease.The Three-Decade Long Journey in Heart Failure Drug Development.New Targets in the Drug Treatment of Heart Failure.Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure.Current and emerging pharmacologic options for the management of patients with chronic and acute decompensated heart failure.Advances in the pharmacotherapy of chronic heart failure with preserved ejection fraction: an ideal opportunity for precision medicine.New developments in the pharmacotherapeutic management of heart failure in elderly patients: concerns and considerations.Saxagliptin and Tadalafil Differentially Alter Cyclic Guanosine Monophosphate (cGMP) Signaling and Left Ventricular Function in Aortic-Banded Mini-Swine.Inhaled Sodium Nitrite Improves Rest and Exercise Hemodynamics in Heart Failure With Preserved Ejection Fraction.The Influence of Nitric Oxide on Soluble Guanylate Cyclase Regulation by Nucleotides: ROLE OF THE PSEUDOSYMMETRIC SITE.Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES).Nitric oxide-sensitive guanylyl cyclase stimulation improves experimental heart failure with preserved ejection fraction.Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study.Phosphodiesterase-5 inhibition in heart failure with preserved ejection fraction: trading therapy for prevention.Urinary cGMP predicts major adverse renal events in patients with mild renal impairment and/or diabetes mellitus before exposure to contrast medium.

P2860

Q24323316-F9A023FA-8A4C-4732-9024-517C79E7D9D0 Q26765101-317F8855-DC1A-4C4D-AA4F-CAD782C2F80B Q33589713-A5804E33-3F62-42F2-A940-F360C1286BA2 Q35164124-917A06EB-773A-41EE-83DC-5C03A8884A60 Q35836147-386F3521-43BF-4727-9911-73D6E90BDF58 Q36054705-FAC37B66-2287-438F-AFDA-8484135E7B66 Q37504067-052A4749-EFA4-455E-B4BE-0E9DD93C08B7 Q38377133-5F67F909-C379-4F46-98C2-F53692F915CA Q38389922-B338294C-6EC6-4F1D-8647-573AFA17938A Q38558614-B4DD030D-A1AF-4465-9552-0F2BC58B694D Q38667210-E532FCD7-2413-415C-9908-22A9A62F37A7 Q38678461-FA601F0E-F734-4D31-9380-E9A7ECFEEE79 Q38737757-5CA64D3B-F14E-4C3F-81CF-C7127C0AFDD4 Q38764956-9E9153C8-B991-4CE4-8A32-5CBEA9B83EFB Q39218629-AB5D9A71-CA9C-4182-B488-E2398760E50D Q40580301-0703103A-FDEE-402E-8C80-4835FF84DEE1 Q41112260-93FE268F-EFE2-410F-8426-E0A4EAF1E393 Q41998443-069C82F0-C32B-4F79-B399-CA104357C7DE Q48640874-A20653FB-88BB-47B2-8FAB-CF350DABD34B Q52375176-C3311735-EE42-4424-AE58-3B4383D23F0B Q52838302-71F2BC8A-5589-4770-A93D-A74A510E73E2 Q54750527-18A8786D-62E9-4119-9023-198FF4839273 Q55113144-B69F4B98-A483-4458-966C-5FEC2D60AA59

P2860

The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction

http://www.wikidata.org/entity/Q27024279

description

2013 nî lūn-bûn

@nan

2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

The cGMP signaling pathway as ...... th preserved ejection fraction

@ast

The cGMP signaling pathway as ...... th preserved ejection fraction

@en

The cGMP signaling pathway as ...... th preserved ejection fraction

@nl

type

label

The cGMP signaling pathway as ...... th preserved ejection fraction

@ast

The cGMP signaling pathway as ...... th preserved ejection fraction

@en

The cGMP signaling pathway as ...... th preserved ejection fraction

@nl

prefLabel

The cGMP signaling pathway as ...... th preserved ejection fraction

@ast

The cGMP signaling pathway as ...... th preserved ejection fraction

@en

The cGMP signaling pathway as ...... th preserved ejection fraction

@nl

P1433

Q27024279-E980B21A-D363-41ED-939E-D2FD47CD0A11

P1476

Q27024279-516009C7-EB91-42A2-8782-04E334A91801

P2093

Q27024279-0DF7D72C-0714-41B7-ADBE-2E8C2ECD94B5

Q27024279-15380DEE-73A0-4280-8D30-D78FC5088929

Q27024279-1E38B1E9-A989-4C16-95D7-12CA4826EFDB

Q27024279-3AA1126E-35FB-41C2-B404-69B0F32CD618

Q27024279-61C978CF-2BE6-438E-894B-98083F648D62

Q27024279-6B8829AD-67D3-4D0A-B9C1-5EBDB7301B6D

Q27024279-A4B740BA-140B-41E4-B4B1-550263CECE32

Q27024279-B4541FE2-8017-43B9-BE73-F84DAF85FA6F

Q27024279-C4BC73B3-9E24-4C23-8E74-25CA562B45AE

Q27024279-F3BB8A9E-FBA0-43B1-A3E9-DC958F86E2DF

P275

Q27024279-7EF8C390-3A61-4E8A-B599-27BBD05ABB3B

P2860

Q27024279-0146D0C5-D7CB-4914-BD35-9B3103B762C6

Q27024279-0336EE1F-2350-45A7-B4F7-C3511E4A9677

Q27024279-04CD2143-759B-4902-A2BD-F6F2B06DFC3D

Q27024279-05E77970-312E-4A78-BEE1-EDA30374FF3B

Q27024279-075DFEC5-BBC4-4C6E-8657-D88FD97AD38B

Q27024279-077D6FB2-39AE-4358-AA69-D73737B45221

Q27024279-09A6F881-FE28-44B6-B7A6-537ECB7340E1

Q27024279-0CEE986E-F0F0-4331-BE5C-02E2E0CCF4BC

Q27024279-0D8F270E-0213-40C2-B662-3395684363F1

Q27024279-0F02738E-B57F-4022-9D65-2E452AE0CEE5

P304

Q27024279-6191C1F8-8953-4680-A55D-BB3E67E25604

P31

Q27024279-7799D947-8332-4A34-AF2D-E1A03F2CED38

Q27024279-B8871524-3761-435E-8539-DCF333333D16

P3181

Q27024279-FA7366F3-B7E3-4615-A785-3066143E5B3B

P356

Q27024279-0A2BEC8E-0700-41E9-92DE-B4FE6663D957

P407

Q27024279-94AB8C0D-95F0-4662-9858-D11054DF73F2

P433

Q27024279-C4AF7B1F-4665-4FDA-9EED-2E778276DD05

P478

Q27024279-57B7ACBF-A192-4368-A6CB-D75FEF6C9E5E

P50

Q27024279-E5F67C24-2241-4697-A4D2-742522BFEE74

P5008

Q27024279-54D4B46F-3E1C-4874-BA41-70FFA0123441

P577

Q27024279-4B39B7F6-3746-4152-8EE5-5A882B11F090

P5875

Q27024279-C5C9EA81-A465-41FD-B699-47381B27952C

P698

Q27024279-C81954A4-4805-42B1-B563-FF36E4635803

P921

Q27024279-A2D8DFE0-3C1B-4202-876B-05D906AC6F63

Q27024279-A531F31A-E5EF-4180-821E-49B4B10DD93B

Q27024279-F1176057-020D-4042-BD58-20D479192FF3

P932

Q27024279-C2D58CB0-2135-491B-A7D9-A8273BBF22CC

P3181

P356

JAHA.113.000536

P1433

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

P1476

The cGMP signaling pathway as ...... th preserved ejection fraction

@en

P2093

B. A. Borlaug

http://www.w3.org/2001/XMLSchema#string

B. Pieske

http://www.w3.org/2001/XMLSchema#string

J. C. Burnett

http://www.w3.org/2001/XMLSchema#string

J.-P. Stasch

http://www.w3.org/2001/XMLSchema#string

L. Roessig

http://www.w3.org/2001/XMLSchema#string

M. Gheorghiade

http://www.w3.org/2001/XMLSchema#string

M. Vaduganathan

http://www.w3.org/2001/XMLSchema#string

S. D. Solomon

http://www.w3.org/2001/XMLSchema#string

S. J. Greene

http://www.w3.org/2001/XMLSchema#string

W. J. Paulus

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Uncoupled cardiac nitric oxide synthase mediates diastolic dysfunction

NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential

A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation

Heart failure with normal left ventricular ejection fraction

Trends in prevalence and outcome of heart failure with preserved ejection fraction

Outcome of heart failure with preserved ejection fraction in a population-based study

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the

MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts

Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms

Effect of endurance training on the determinants of peak exercise oxygen consumption in elderly patients with stable compensated heart failure and preserved ejection fraction.

P304

e000536

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2200104

http://www.w3.org/2001/XMLSchema#string

P356

10.1161/JAHA.113.000536

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

P5008

P577

2013-12-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259319675

http://www.w3.org/2001/XMLSchema#string

P698

24334823

http://www.w3.org/2001/XMLSchema#string

P921

heterocyclic compound

P932

3886746

http://www.w3.org/2001/XMLSchema#string